Related by context. All words. (Click for frequent words.) 69 recurrent glioblastoma 69 Aplidin 68 Xanafide 68 PROCHYMAL 68 Surgical resection 67 biliary tract cancer 67 deforolimus 67 Ceflatonin 67 ixabepilone 67 Gleevec resistant 67 CBLC# 67 relapsed ovarian cancer 67 sorafenib Nexavar 67 axitinib 67 malignant pleural mesothelioma 67 enzastaurin 67 SNT MC# 67 CA4P 66 gefitinib Iressa 66 IMA# 66 ZACTIMA 66 BRAF inhibitor 66 noninfectious uveitis 66 OHR/AVR# 66 Vandetanib 66 Hepatocellular Carcinoma HCC 66 Onconase 66 MEK inhibitors 66 pancreatic NET 66 Allovectin 7 ® 66 receptor tyrosine kinase inhibitor 66 taxane therapy 65 haematological cancers 65 pertuzumab 65 chemoradiotherapy 65 anticancer therapy 65 radiation sensitizer 65 cediranib 65 ToGA 65 Hsp# inhibition 65 thalidomide Thalomid 65 TTF Therapy 65 riociguat 65 mTOR inhibition 65 TEMODAL 65 neoadjuvant treatment 65 elacytarabine 65 molecularly targeted 65 SIR Spheres 65 angiogenesis inhibitor 65 OMAPRO 65 metastatic gastric 65 anti angiogenic agents 65 chemopreventive agent 65 TroVax ® 65 TG# [003] 65 choroidal vasculopathy 65 UPLYSO 65 refractory metastatic 65 castration resistant prostate cancer 65 pancreatic adenocarcinoma 65 vidofludimus 65 XmAb# 65 demonstrated antitumor activity 65 antiangiogenic therapy 65 LHRH receptor positive 65 vemurafenib 65 refractory acute myeloid 65 erlotinib Tarceva 65 olaparib 64 CTEPH 64 multiple myeloma MM 64 JAK inhibitors 64 myeloproliferative disorders 64 basal cell carcinoma BCC 64 gastrointestinal stromal tumors 64 CYT# potent vascular disrupting 64 Bezielle 64 diagnostic biomarker 64 recurrent NSCLC 64 metastatic bladder 64 DCVax R 64 depsipeptide 64 Nexavar sorafenib 64 EndoTAG TM -1 64 regorafenib 64 EGFR inhibitors 64 squamous cell lung cancer 64 bone metastasis 64 neovascular diseases 64 epithelial tumors 64 unresectable tumors 64 angiogenesis inhibition 64 Doxil ® 64 HuMax CD4 64 preclinically 64 castrate resistant prostate cancer 64 anti angiogenic drugs 64 Pemetrexed 64 gemcitabine Gemzar 64 Daclizumab 64 Symadex 64 YONDELIS 64 Genasense ® 64 bendamustine 64 oral Xeloda 64 bortezomib Velcade 64 Pertuzumab 64 trabectedin 64 PARP inhibitors 64 xenograft models 64 relapsed SCLC 64 HuMax EGFr 64 KRAS status 64 Ophena TM 64 BRAF inhibitors 64 PARP inhibition 64 BCR ABL inhibitors 64 chemotherapeutic regimens 64 BrachySil TM 64 interferon beta therapy 64 metastatic kidney 64 antiarrhythmic 64 pancreatic neuroendocrine tumors 64 metastatic liver 64 Tyrima 64 lung metastasis 64 molecularly targeted therapy 64 Crizotinib 64 kidney urologic 64 prognostic markers 64 PI3K inhibitors 64 allogeneic HSCT 64 curative therapy 64 neuroprotectant 64 pancreatic islet cell 64 alvespimycin 64 lenalidomide dexamethasone 63 CIMZIA ™ 63 EndoTAGTM 1 63 anti angiogenic agent 63 MAGE A3 ASCI 63 Dasatinib 63 GRN# 63 Gleevec imatinib 63 dasatinib Sprycel 63 Certolizumab pegol 63 Temsirolimus 63 ALK inhibitors 63 liver metastasis 63 tubulin inhibitor 63 SUTENT 63 neratinib 63 gastric adenocarcinoma 63 metastatic RCC 63 pemphigus vulgaris 63 relapsed MM 63 lymphoid malignancies 63 imatinib Gleevec 63 biotherapy 63 non metastatic osteosarcoma 63 taxane chemotherapy 63 obatoclax 63 lapatinib Tykerb 63 renal tumors 63 amrubicin 63 OncoVEX GM CSF 63 Angiolix 63 stratifying patients 63 concurrent chemoradiation 63 ProSavin 63 renal carcinoma 63 HER2 positive metastatic breast 63 gastrointestinal stromal tumors GIST 63 TYSABRI natalizumab 63 bevacizumab Avastin ® 63 farletuzumab 63 Zolinza 63 Sanofi Aventis Taxotere 63 recurrent GBM 63 Cloretazine 63 vascular disrupting agents 63 Squalamine 63 Azedra 63 Torisel 63 vismodegib 63 metastatic malignant 63 YONDELIS R 63 Kevetrin ™ 63 MGd 63 Irinotecan 63 nonsmall cell lung cancer 63 mTOR inhibitors 63 ELACYT 63 Amplimexon 63 Archexin 63 metastatic renal cell carcinoma 63 Halaven 63 Amrubicin 63 AA amyloidosis 63 fibrotic disease 63 vascular disrupting agent 63 nonmelanoma skin cancers 63 glioblastoma multiforme GBM 63 localized renal 63 PNH patients 63 non resectable metastatic 63 lumiliximab 63 antiangiogenesis 63 investigational therapies 63 Abiraterone 63 multi kinase inhibitor 63 lupus nephritis 63 nonmetastatic 63 humanised monoclonal antibody 63 diabetic macular edema 63 Aflibercept 63 hematological malignancy 63 pharmacokinetic interactions 63 prostate carcinoma 63 hormone refractory 63 Tesmilifene 63 relapsed leukemia 63 SCCHN 63 forodesine 63 AA Amyloidosis 63 CTAP# Capsules 63 DACH platinum 63 Vectibix monotherapy 63 anticancer compound 63 hypervascular tumors 63 HSP# inhibitor 63 skeletal metastases 62 fallopian tube carcinoma 62 TORISEL 62 antiangiogenic agents 62 malignant lymphomas 62 Arranon 62 chemoresistant 62 Erlotinib 62 sunitinib malate 62 immatics 62 Troxatyl 62 neoadjuvant therapy 62 malignant ascites 62 nilotinib Tasigna 62 HuLuc# 62 QuadraSphere 62 JAK3 62 Deforolimus 62 cytoreduction 62 decitabine 62 rituximab Rituxan 62 Glivec imatinib 62 GRASPA ® 62 immunosuppressive regimens 62 Panzem 62 Akt inhibitor 62 zanolimumab 62 RhuDex ® 62 LHRH agonists 62 medullary thyroid cancer 62 Gefitinib 62 bevacizumab Avastin 62 Orazol 62 proteasome inhibitor 62 KIACTA ™ 62 hepatocellular carcinoma HCC 62 INC# 62 non squamous NSCLC 62 sunitinib Sutent 62 Tarceva TM 62 anticancer therapies 62 ALA PDT 62 imatinib resistance 62 Ophena 62 Fingolimod 62 AML acute myeloid 62 Afatinib 62 CHOP chemotherapy 62 pediatric malignancies 62 metaglidasen 62 differentiated thyroid 62 multitargeted 62 psoriatic arthritis PsA 62 Traficet EN 62 chemotherapeutic regimen 62 PI3K/Akt pathway inhibitor 62 mycosis fungoides 62 benign neoplasms 62 cilengitide 62 OMNARIS HFA 62 indolent lymphomas 62 Shark cartilage 62 pan HDAC inhibitor 62 cytokine refractory 62 therapeutic modality 62 androgen independent 62 PLX cells 62 SERMs 62 talabostat 62 predictive biomarkers 62 MMP inhibitors 62 PSMA ADC 62 Sorafenib 62 FOLFIRINOX 62 recurrent malignant glioma 62 anti VEGF 62 nodal metastasis 62 BRAF V#E mutation 62 Allovectin 7 62 ErbB2 positive 62 Chronic lymphocytic leukemia 62 cetuximab Erbitux 62 Panzem R NCD 62 cervical carcinoma 62 mRCC 62 Aviptadil 62 Gleevec imatinib mesylate 62 Provecta 62 K ras mutations 62 recurrent glioblastoma multiforme 62 alkylating agent 62 VEGF inhibitor 62 ximelagatran 62 efaproxiral 62 premalignant lesions 62 gemcitabine carboplatin 62 ganetespib 62 advanced metastatic prostate 62 Avastin bevacizumab 62 molecular subtypes 62 Alemtuzumab 62 erlotinib Tarceva ® 62 Tarceva erlotinib 62 Oxaliplatin 62 chronic periodontitis 62 Sudhir Agrawal D.Phil 62 Neuvenge 62 TNF blocker therapy 62 invasive carcinoma 62 deferiprone 62 ovarian suppression 62 EGFR pathway 62 membranous nephropathy 62 PARP inhibitor 62 EGFR mutation positive 62 #F FDG PET 62 imatinib Gleevec ® 62 endostatin 62 antiangiogenic agent 62 novel oral anticoagulant 62 standard chemotherapy regimens 62 entinostat 62 AZILECT ® 62 Dacogen decitabine 62 afamelanotide 62 therapeutic armamentarium 62 Zybrestat 62 invasive candidiasis 62 cytotoxic therapy 62 VAPRISOL 62 metastatic neuroendocrine tumors 62 sJIA 62 metastatic colorectal 62 EchoCRT 62 thetreatment 62 oral antiviral 62 tyrosine kinase inhibitors 62 Carfilzomib 62 BZL# 62 ProLindac TM 62 plasma kallikrein inhibitor 62 IGF 1R inhibitor 62 complete cytogenetic response 62 Rituxan rituximab 62 AEG# 62 superficial bladder cancer 62 RRMS patients 62 relapsed AML 62 carcinoid 62 Golimumab 62 indibulin 62 relapsed multiple myeloma 62 radiochemotherapy 62 StemEx R 62 SUTENT ® 62 EGFR tyrosine kinase inhibitors 62 pain palliation 61 AP# [003] 61 OncoVEX 61 Gemzar ® 61 tanespimycin 61 Eli Lilly Gemzar 61 ADAGIO study 61 MYCN amplification 61 Cimzia TM 61 recurrent ovarian 61 resectable 61 fluoropyrimidine 61 HyACT 61 colorectal liver metastases 61 Novartis Gleevec 61 pancreatic carcinoma 61 huC# DM4 61 prostate carcinomas 61 IRX 2 61 photodynamic therapy PDT 61 pediatric acute lymphoblastic 61 advanced hepatocellular carcinoma 61 anti arrhythmic drug 61 nosocomial pneumonia 61 DU #b 61 biologic therapies 61 pazopanib 61 inoperable pancreatic cancer 61 Fludara ® 61 Vidaza azacitidine 61 Trastuzumab 61 Genz # 61 goserelin 61 molecular abnormalities 61 ASONEP 61 commercialize deforolimus 61 antiproliferative effects 61 BRAF mutation 61 pre malignant lesions 61 etanercept Enbrel 61 antitumor effect 61 myeloproliferative diseases 61 indolent NHL 61 therapeutic regimens 61 preoperative chemotherapy 61 metastatic renal 61 trastuzumab DM1 61 HGS# 61 trastuzumab Herceptin ® 61 anti fibrotic 61 ALCL 61 tipifarnib 61 Virulizin ® 61 temozolomide Temodar 61 leukemia AML 61 GISTs 61 histologic diagnosis 61 acyclovir Lauriad R 61 ARIKACE ™ 61 relapsed ALL 61 phase IIb clinical 61 Quinamed 61 ENMD # 61 Teriflunomide 61 placebo controlled clinical 61 trastuzumab Herceptin 61 plasminogen activators 61 pegylated liposomal doxorubicin 61 ZD# [001] 61 platinum refractory 61 immune modulating 61 peritoneal carcinomatosis 61 mucinous 61 BRIM2 61 Taxol paclitaxel 61 TheraSphere 61 iniparib 61 pharmacologic intervention 61 Papillary 61 kinase inhibition 61 Intravenous CP 61 Angiox R 61 JAK inhibitor 61 Pfizer Sutent 61 ACZ# 61 refractory CLL 61 microtubule targeting 61 Xelox 61 serous ovarian cancer 61 TransMID TM 61 Trofex 61 ADPKD 61 KRAS oncogene 61 targeted radiotherapeutic 61 Gleevec Glivec 61 Rituxan MabThera 61 chemotherapy cisplatin 61 HER2 positive cancers 61 surgical debulking 61 acetonide FA 61 Mipomersen 61 cisplatin chemotherapy 61 antitumour activity 61 antithrombotic therapy 61 ZOLINZA 61 p# biomarker 61 Zarnestra 61 Proxinium TM 61 Vicinium TM 61 A3 adenosine receptor 61 acute leukemias 61 CytoFabTM 61 Tarvacin 61 relapsing remitting MS RRMS 61 colorectal carcinoma 61 convenient dosing regimens 61 locoregional recurrence 61 tafamidis 61 postoperative chemotherapy 61 Votrient 61 bone metastases 61 genomic biomarker 61 mTOR inhibitor 61 CGEN # 61 VA# [002] 61 molecular biomarkers 61 refractory colorectal cancer 61 bexarotene 61 paclitaxel Taxol 61 Velcade bortezomib 61 neoadjuvant 61 GIST tumors 61 pituitary adenomas 61 haematological malignancies 61 TheraCIM 61 HQK 61 MAPK pathway 61 anti TNF alpha 61 INCB# [003] 61 small molecule activators 61 BCG refractory 61 Vorinostat 61 phase IIb trial 61 Neovastat 61 reslizumab 61 metastatic renal cell 61 diagnostic modality 61 triphendiol 61 hepatocellular carcinoma 61 pediatric Crohn disease 61 EGFR TKI 61 malignant brain 61 metastatic hormone refractory 61 Xeloda capecitabine 61 CINQUIL 61 choroidal neovascularization 61 LHRH antagonists 61 temsirolimus 61 untreated metastatic melanoma 61 Omnitarg 61 Advagraf 61 refractory CTCL 61 tocilizumab 61 Sezary syndrome 61 Catena ® 61 oral picoplatin 61 thromboembolic disease 61 cardiotoxic 61 Revimmune 61 fosbretabulin 61 pegfilgrastim 61 MGUS 61 DFMO 61 Phase #b/#a clinical 61 prognostic marker 61 Interferon beta 61 IDH1 mutation 61 PXD# 61 molecularly targeted therapies 61 oral FTY# 61 Hodgkin lymphoma HL 61 EndoTAG TM 61 vorinostat 61 histologies 61 mutated KRAS gene 61 recurrent metastatic 61 therapeutic monoclonal antibody 61 proteasome inhibitors 61 Aggrastat ® tirofiban hydrochloride 61 EOquin TM 61 Kinase inhibitors 61 metastatic malignant melanoma 61 Fibrillex TM 61 GW# [003] 61 ATL/TV# 61 refractory AML 61 marketed pegylated interferons 61 Pseudomonas aeruginosa infections 61 BNC# 61 adjuvant therapies 61 STRIDE PD 61 neoadjuvant setting 60 GV# [001] 60 LEUKINE 60 AMN# [001] 60 inhibit metastasis 60 Fabry Disease 60 sentinel lymph node biopsy 60 calcineurin inhibitors 60 Tavocept 60 anti angiogenic 60 malignancies 60 BEMA TM Fentanyl 60 EOquin 60 imexon 60 TACI Ig 60 macrolide antibiotics 60 BAY #-# 60 prognostic indicator 60 paclitaxel poliglumex 60 heavily pretreated 60 lymphomas leukemias 60 corticosteroid dexamethasone 60 tranilast 60 Neulasta ® 60 taxane refractory 60 prostate cancer CaP 60 Cytolin R 60 abiraterone acetate 60 Raptiva ® 60 lomitapide 60 MRgFUS 60 multimodality therapy 60 Silodosin 60 aerosolized KL4 surfactant 60 JAK2 inhibitor 60 chemotherapeutic drug 60 tumors GIST 60 volociximab 60 sorafenib tablets 60 hepatic metastases 60 Cotara 60 ANAVEX #-# [001] 60 Genentech Herceptin 60 histone deacetylase HDAC inhibitor 60 PROLARIS 60 precursor lesions 60 colorectal adenocarcinoma 60 Anaplastic 60 IL# PE#QQR 60 recurrent ovarian cancer 60 myelofibrosis polycythemia vera 60 stage IIIB IV 60 LB# [003] 60 proteomic biomarkers 60 delafloxacin 60 drug eluting stent DES 60 biologic therapy 60 Arzerra ofatumumab 60 Herceptin trastuzumab 60 RNAi therapeutic targeting 60 ThermoDox R 60 paclitaxel Taxol R 60 Enzastaurin 60 Reverset 60 Isolagen Therapy 60 Neuradiab 60 ATL# [001] 60 druggable targets 60 ulimorelin 60 drug GAP #B# 60 VIDAZA 60 apremilast 60 samalizumab 60 Renal Cell Carcinoma RCC 60 epigenetic therapies 60 MabCampath 60 TTR amyloidosis 60 RhuDex R 60 miglustat 60 alemtuzumab treated 60 HER2 positivity 60 cinacalcet 60 rFVIIa 60 Benlysta belimumab 60 ON #.Na 60 VEGF inhibition 60 Mepact 60 monoclonal antibody therapies 60 evaluating REVLIMID 60 pancreatic prostate 60 hereditary deficiency 60 chemoembolization 60 neuroendocrine carcinoma 60 TNF alpha inhibitor 60 breast cancer subtypes 60 relapsing multiple sclerosis 60 KRAS mutation 60 Glioblastoma Multiforme 60 vascular thrombosis 60 metastatic lesions 60 OvaRex ® MAb 60 demethylating agents 60 Rasagiline 60 ADVEXIN therapy 60 Platinol ® cisplatin 60 urothelial bladder cancer 60 anticancer agent 60 abiraterone 60 engineered RAP peptides 60 elotuzumab 60 vinca alkaloids 60 Sebivo 60 Epratuzumab 60 Axitinib 60 NATRECOR ® 60 Metastatic breast cancer 60 Vitaxin 60 ReN# 60 BCR ABL inhibitor 60 ProMune 60 Smac mimetics 60 castration resistant 60 galiximab 60 Curaxin 60 potent antiproliferative 60 visilizumab 60 CA9 SCAN 60 OvaRex R 60 Pagoclone 60 Factor Xa inhibitor 60 hormone refractory metastatic prostate 60 Mitoxantrone 60 leukaemias 60 atacicept 60 tesmilifene 60 Advexin 60 bardoxolone methyl 60 Sphingomab 60 PFO closure 60 advanced medullary thyroid 60 DOXIL 60 Ataluren 60 pemetrexed Alimta 60 tyrosine kinase inhibitor 60 teriflunomide 60 PrevOnco ™ 60 anti EGFR antibody 60 bladder carcinoma 60 multikinase inhibitor 60 symptomatic paroxysmal AF 60 radiotherapeutic 60 invasive lobular carcinoma 60 Modrenal 60 Degarelix 60 NV1FGF 60 Abiraterone acetate 60 Muraglitazar 60 velafermin 60 spontaneous regression 60 docetaxel Taxotere ® 60 Nanobody 60 Src inhibitors 60 schizophrenia CIAS 60 NP2 Enkephalin 60 generation purine nucleoside 60 arterial thrombosis 60 Dendreon Provenge 60 ImmunoVEX HSV2 60 lung pancreatic 60 eprotirome 60 Neoadjuvant chemotherapy 60 evaluating tivozanib 60 gastric carcinoma 60 chimeric monoclonal antibody 60 docetaxel chemotherapy 60 refractory ovarian cancer 60 ProLindac 60 mycophenolate mofetil 60 HGPIN 60 SERCA2a 60 Certican 60 lung fibrosis 60 huN# DM1 60 XYOTAX TM 60 BRAF mutations 60 esophageal candidiasis 60 IORT 60 gemcitabine chemotherapy 60 chromosomal rearrangement 60 Lenalidomide 60 oxaliplatin Eloxatin 60 Radical prostatectomy 60 KRAS mutations occur 60 B7 H3 60 Pirfenidone 60 nonalcoholic steatohepatitis NASH 60 hypophosphatasia 60 Factor VIIa 60 Campath alemtuzumab 60 favorable pharmacokinetic profile 60 cangrelor 60 benign prostatic hypertrophy BPH 60 Combination therapy 60 stem cell transplantations 60 DXL# 60 Fludarabine 60 Everolimus 60 Octreolin 60 Eribulin 60 pharmacokinetic PK study 60 alemtuzumab Campath 60 CCX# 60 Erbitux cetuximab 60 secondary hyperparathyroidism 60 Sutent sunitinib 60 SSc 60 Revlimid lenalidomide 60 systemic ALCL 60 extracranial 60 topotecan 60 tumor histology 60 novel VDA molecule 60 ruxolitinib 60 tumor subtypes 60 endocrine therapies 60 refractory Hodgkin 60 ara C 60 Vernakalant 60 candidemia 60 personalized immunotherapy 60 gastrointestinal stromal tumor GIST 60 zalutumumab 60 metastatic CRC 60 immunomodulation 60 multicentric 60 APOPTONE 60 irinotecan chemotherapy 60 cMET 60 induced macular edema 60 parthenolide 60 Anti VEGF 60 efalizumab 60 HCV infections 60 hepatocellular cancer 60 BioSTAR R 60 Evoltra ® 59 gastrointestinal stromal tumors GISTs 59 resistant ovarian cancer 59 Folotyn 59 gastric cancers 59 adjuvant radiotherapy 59 virotherapy 59 masitinib 59 chemotherapeutic 59 PLX# 59 idiopathic pulmonary fibrosis IPF 59 leukemia ALL 59 Relapsing remitting MS 59 esophagogastric 59 percutaneous biopsy 59 temozolomide 59 cutaneous melanoma 59 CIMZIA TM 59 cytotoxics 59 EGFR mutations 59 GFT# 59 TriRima 59 Cethrin 59 HCV protease inhibitors 59 imatinib mesylate Gleevec 59 photodynamic 59 panobinostat 59 Cristofanilli 59 oral ridaforolimus 59 doublet chemotherapy 59 anti leukemic 59 HeFH 59 CRVO 59 Vascugel ® 59 solid tumors 59 dirucotide MBP# 59 myeloablative 59 estramustine 59 oral deforolimus 59 pegaptanib 59 Aurora kinase 59 G#DT 59 Treanda 59 Annamycin 59 OvaRex MAb 59 RhuDex TM 59 paclitaxel Taxol ® 59 Cytoxan 59 overlapping toxicities 59 EGFR tyrosine kinase inhibitor 59 adecatumumab 59 JAK2 inhibitors 59 LymphoStat B belimumab 59 CCR5 inhibitor 59 plasma kallikrein 59 oral salmon calcitonin 59 Protelos 59 multicenter trials 59 remission induction 59 carcinoma HCC 59 Squamous 59 Litx 59 Dapagliflozin 59 Li Fraumeni Syndrome 59 Dacogen injection 59 dasatinib 59 OncoGel 59 hematologic disorders 59 Hydroxyurea 59 rALLy clinical trial 59 PEP# [003] 59 malignant pancreatic 59 malignant growths 59 metastatic cancers 59 Metastatic colorectal cancer 59 recurrent glioblastoma multiforme GBM 59 Ranibizumab 59 GeneICE 59 histologic subtype 59 actinic keratosis 59 Insegia 59 Vaprisol 59 dermatologic diseases 59 medically inoperable 59 relapsed refractory multiple myeloma 59 S/GSK# 59 carcinoid tumors 59 denileukin diftitox 59 idiopathic myelofibrosis 59 inhibit EGFR 59 PathFinderTG 59 radezolid 59 Nexavar ® 59 ticagrelor Brilinta 59 neuroendocrine tumors 59 Nuvion 59 ponatinib 59 COPAXONE R 59 Phase Ib study 59 sargramostim 59 hematological indications 59 EGFR mutant 59 vandetanib 59 lenalidomide Revlimid R 59 eltrombopag 59 fallopian tube cancers 59 mouse xenograft models 59 ImmuKnow assay 59 CMV retinitis 59 MALT lymphoma 59 Telintra 59 Hedgehog inhibitor 59 CytoFab 59 nucleoside analogue 59 MYDICAR ® 59 Phase IIb clinical trials 59 romidepsin 59 Targretin 59 metastatic lung cancer 59 urothelial cancer 59 vinca alkaloid 59 CRLX# 59 OXi# 59 florbetaben 59 trabedersen 59 renal cell carcinomas 59 treat chronic sinusitis 59 Tanespimycin 59 cytoreductive surgery 59 antiplatelet therapies 59 Eraxis 59 tumor necrosis 59 TGFBR1 * 6A 59 bosutinib 59 drug ISA# 59 BMS# 59 Anavex #-# 59 Ozurdex 59 colorectal lung 59 LY# [003] 59 neoplastic lesions 59 cranial radiation 59 CAPHOSOL 59 intravenous bisphosphonates 59 oral rivaroxaban 59 novel therapeutic antibodies 59 Ixempra 59 Evoltra 59 heavily pretreated patients 59 pathologic myopia 59 SIR Spheres microspheres 59 small molecule tyrosine 59 Sym# 59 anticancer therapeutics 59 Femara letrozole 59 Glioblastoma multiforme 59 targeting CD# 59 percutaneous cryoablation 59 neovascular AMD 59 chronic myocardial ischemia 59 ALK inhibitor 59 Ridaforolimus 59 ranibizumab Lucentis 59 Bevacizumab 59 antimetabolite